Safety profile of once-weekly subcutaneous semaglutide in a real-world adult population with type 2 diabetes

被引：0
|
作者：
Yale, J. -F. [1 ]
Major-Pedersen, A. [2 ]
Catarig, A. -M. [3 ]
Jain, R. G. [4 ]
Menzen, M. [5 ]
Holmes, P. [6 ]
机构：
[1] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[2] Novo Nordisk AS, Global Safety, Soborg, Denmark
[3] Novo Nordisk AS, Soborg, Denmark
[4] Novo Nordisk Serv Ctr Private Ltd, Biostat, EPIP Area Whitefield, Mindcomp Tech Pk,2nd Phase, Bangalore, Karnataka, India
[5] Gemeinschaftskrankenhaus Bonn, Innere Med Diabetol, Bonn, Germany
[6] St Georges Med Practice, Yarm Rd, Darlington, Durham, England
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
670
引用
收藏
页码：S339 / S340
页数：2
相关论文
共 50 条
  • [21] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [22] Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study
    Shi, Chenyang
    Tan, Yijiong
    Hu, Shanshan
    Qin, Yingyi
    Tang, Yuanjun
    Wang, Yufan
    Fan, Guorong
    DIABETES OBESITY & METABOLISM, 2024, 26 (06): : 2513 - 2516
  • [23] Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes
    Vilsboll, Tina
    Lindahl, Caroline O.
    Nielsen, Nick F.
    Tikkanen, Christian K.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1740 - 1749
  • [24] Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the CanadianLMCdiabetes registry (SPAREstudy)
    Brown, Ruth E.
    Bech, Peter G.
    Aronson, Ronnie
    DIABETES OBESITY & METABOLISM, 2020, 22 (11): : 2013 - 2020
  • [25] Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
    Buse, John B.
    Christensen, Helene Nordahl
    Harty, Brian J.
    Mitchell, Julie
    Soule, Benjamin P.
    Zacherle, Emily
    Cziraky, Mark
    Willey, Vincent J.
    BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (03)
  • [26] Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
    Petri, Kristin Cecilie Carlsson
    Ingwersen, Steen Hvass
    Flint, Anne
    Zacho, Jeppe
    Overgaard, Rune Viig
    DIABETES THERAPY, 2018, 9 (04) : 1533 - 1547
  • [27] Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study
    Rudofsky, Gottfried
    Catarig, Andrei-Mircea
    Favre, Lucie
    Grau, Katrine
    Hafliger, Susan
    Thomann, Robert
    Schultes, Bernd
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 178
  • [28] Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
    Kristin Cecilie Carlsson Petri
    Steen Hvass Ingwersen
    Anne Flint
    Jeppe Zacho
    Rune Viig Overgaard
    Diabetes Therapy, 2018, 9 : 1533 - 1547
  • [29] Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
    Lingvay, Ildiko
    Benamar, Malik
    Chen, Liming
    Fu, Ariel
    Jodar, Esteban
    Nishida, Tomoyuki
    Riveline, Jean-Pierre
    Yabe, Daisuke
    Zueger, Thomas
    Rea, Rosangela
    DIABETOLOGIA, 2025, : 739 - 751
  • [30] Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
    Byung-Wan Lee
    Young Min Cho
    Sin Gon Kim
    Seung-Hyun Ko
    Soo Lim
    Amine Dahaoui
    Jin Sook Jeong
    Hyo Jin Lim
    Jae Myung Yu
    Diabetes Therapy, 2024, 15 : 547 - 563
12345